Last reviewed · How we verify
Alloplast
Alloplast is a Small molecule drug developed by Ain Shams University. It is currently in Phase 3 development. Also known as: Beta tri-calcuim phosphate.
Alloplast is a bone substitute used in dental procedures, specifically for conditions such as alveolar ridge enlargement, dental implant failure, bone loss, alveolar fenestration, and dehiscence. It is one of the interventions studied in clinical trials, including a trial at Ain Shams University that compared its effectiveness with allograft and toothgraft for alveolar ridge preservation.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Alloplast |
|---|---|
| Also known as | Beta tri-calcuim phosphate |
| Sponsor | Ain Shams University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Alveolar Ridge Preservation With Putty Allograft vs. Putty Alloplast Graft (PHASE4)
- Grafting of the Peri-implant Bony Defects Around Immediate Implants Using Xenogenic Versus Alloplastic Sticky Grafts: Randomized Controlled Clinical Trial (NA)
- Histological Analysis of Osteogenic Potential of Biphasic Calcium Phosphate (PHASE4)
- Immediate Implant With Different Filling Materials (NA)
- Alveolar Ridge Preservation Using Different Bone Substitutes (PHASE3)
- Evaluation of β-tricalcium Phosphate/Calcium Sulfate Versus Allografts (NA)
- Socket Preservation Using Socket Shield Technique Comparison of Socket Preservation Using Socket Shield Technique With Autogenous Dentin Graft Versus Alloplast Graft Material (NA)
- Implant Placement in the Preserved Socket Using Socket Shield Technique With Autogenous Dentin Graft Versus Preserved Socket Using Socket Shield With Alloplast (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Alloplast CI brief — competitive landscape report
- Alloplast updates RSS · CI watch RSS
- Ain Shams University portfolio CI
Frequently asked questions about Alloplast
What is Alloplast?
Who makes Alloplast?
Is Alloplast also known as anything else?
What development phase is Alloplast in?
Related
- Manufacturer: Ain Shams University — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Beta tri-calcuim phosphate
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing